Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
145
NCT01691313
Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 30, 2012
Completion: Oct 31, 2013
NCT02454283
Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Phase: Phase 3
Start: Sep 30, 2015
Completion: Nov 30, 2015